Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other subtypes of the disease. Because alterations and mutations for which targeted therapies are approved are uncommon in squamous cell NSCLC, treatment remains challenging. In addition, unique clinicopathologic characteristics and patient factors such as older age, advanced disease at diagnosis, and a higher incidence of comorbidities complicate effective treatment planning for patients with metastatic disease (Socinski et al, 2018). Therefore, it is essential that members of the multidisciplinary team maintain a comprehensive understanding of the efficacy and safety profiles of emerging therapies in order to inform treatment selection and adverse event management. In this activity, Mark G. Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®, will update clinicians on strategies for developing personalized management plans to optimize the treatment and survivorship of patients with metastatic squamous cell NSCLC.
Get the latest updates delivered to your inbox!